High transduction efficiency of circulating first trimester fetal mesenchymal stem cells: potential targets for in utero ex vivo gene therapy

We recently reported the existence of fetal mesenchymal stem cells in first trimester fetal blood. Here we demonstrate that fetal mesenchymal stem cells from as early as eight weeks of gestation can be retrovirally transduced with 99% efficiency without selection. Circulating fetal mesenchymal stem...

Full description

Saved in:
Bibliographic Details
Published inBJOG : an international journal of obstetrics and gynaecology Vol. 109; no. 8; pp. 952 - 954
Main Authors Campagnoli, Cesare, Bellantuono, Ilaria, Kumar, Sailesh, Fairbairn, Leslie J., Roberts, Irene, Fisk, Nicholas M.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.08.2002
Blackwell
Subjects
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Applied cell therapy and gene therapy
Biological and medical sciences
Female
Fetal Blood - cytology
Fetus - cytology
Flow Cytometry
Genetic Therapy
Humans
Medical sciences
Mesoderm - cytology
Pregnancy
Pregnancy Trimester, First
Stem Cells - cytology
Transduction, Genetic - methods
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Virus
Human
Blood circulation
Efficiency
Stem cell
Mesenchyma
Retroviridae
Fetus
First trimester
Transduction
Gene therapy
Preliminary test
Online AccessGet full text

Cover

More Information
Summary:We recently reported the existence of fetal mesenchymal stem cells in first trimester fetal blood. Here we demonstrate that fetal mesenchymal stem cells from as early as eight weeks of gestation can be retrovirally transduced with 99% efficiency without selection. Circulating fetal mesenchymal stem cells are known to readily expand and differentiate into multiple tissue types both in vitro and in vivo, and might be suitable vehicles for prenatal gene delivery. With advances in early fetal blood sampling techniques, we suggest that genetic disorders causing irreversible damage before birth could be treated in utero in the late first/early second trimester by genetically manipulated autologous fetal stem cells.
Bibliography:These authors contributed equally to this work.
Stem Cell Research Laboratory, Giving for Living Research Centre, Royal Manchester Children Hospital, Manchester, UK.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1470-0328
1471-0528
DOI:10.1111/j.1471-0528.2002.t01-1-02011.x